InsidersTradesSigma
Follow the 인투셀 share price and the full directors' dealings record of the company, a listed equity based in South Korea. Shares are quoted on KR KR, under the authority of DART (FSS). Operating in the Health Care sector, 인투셀 has logged 3 public disclosures. Market capitalisation: €254.9bn. The latest transaction was reported on 5 June 2026 (Purchase). Among the most active insiders: 이향숙. The full history is openly available.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
인투셀 is a healthcare and pharmaceutical company listed on the XKRX market. It focuses on developing innovative therapies and health solutions.